Cristina Rondinone, Head of Cardiovascular and Metabolic Diseases
Innovative Medicines at MedImmune said: The consortium brings several combined years of drug discovery and scientific expertise from academic and pharmaceutical partners, which will accelerate discovery of new pathways to help us deliver meaningful biologic medicines for patients with chronic kidney diseases.
Signaling molecules such as hormones regulating the control of sugar and fat metabolism and inflammation were changed, resembling the very subtle start of negative health effects similar to that affecting those with metabolic disease
Lack of sleep and obesity have been associated with an increased risk of cardiovascular and metabolic diseases
in adults and young children.
This research may also be a first step in explaining a possible correlation between bone health and other metabolic diseases
such as osteoporosis," he added.
Given Peptimmune's experienced management team, clinical development expertise in both autoimmune and metabolic disease
, and their commitment to moving this program forward, we think they are an excellent partner.
Because three of the children with positive tandem MS metabolic screens did not have fat in their livers, performing postmortem metabolic disease
screening on the basis of abnormal liver pathology might not have identified all affected children.
A Clinical Guide to Inherited Metabolic Diseases
, 2nd edition.
Not only do these findings identify TRPV4 as a compelling therapeutic target, but they continue to build out our understanding of the role of brown fat in humans and in developing novel brown fat treatments for metabolic disease
Contact: Direct questions about scientific and research issues to Salvatore Sechi, Division of Diabetes, Endocrinology, and Metabolic Diseases
, NIDDK, 6707 Democracy Blvd, Rm 611, Bethesda, MD 20892-5460 USA, 301-594-8814, fax: 301-480-2688, e-mail: ss24q@nih.
Peptimmune is a privately held biotechnology company focused on development of therapeutics for the treatment of autoimmune and metabolic diseases
New, first in class drugs are needed for metabolic disease
and DBM has multiple targets and multiple human cell platforms optimized for this effort.
Furthermore, I will analyze mucosa-associated microbiota in metabolic disease
by using mouse models and samples from human patients.